Neoplasms

All Conditions

Adenocarcinoma

Carcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Antineoplastic Agents

All Drugs and Chemicals

Anti-Infective Agents

Capecitabine

Epirubicin

Oxaliplatin

Panitumumab

Anti-Bacterial Agents

Antibiotics, Antitubercular

Enzyme Inhibitors

Antineoplastic Agents, Immunological

open-label, single-arm EOXP Epirubicin 50mg/m2 by IV on day 1 of each 21 day cycle, Oxaliplatin 100 mg/m2 by IV on day 1 of each 21 day cycle, Capecitabine 400 mg/m2 twice daily by mouth on days 1-21 of the 21 day cycle Panitumumab - 9mg/kg by IV on day 1 of each 21 day cycle

panitumumab, epirubicin, oxaliplatin, xeloda

David P Ryan, MD

A pilot study to determine the safety of using perioperative panitumumab with EOX (epirubicin, oxaliplatin, and capecitabine) in patients with adenocarcinoma of the esophagus and stomach.

Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma

A Pilot Study of Perioperative Panitumumab in Combination With Epirubicin, Oxaliplatin and Xeloda in Patients With Resectable Gastroesophageal Adenocarcinoma

Safety and tolerability were measured by assessing the number of participants able to complete 3 cycles of pre-operative chemotherapy

percentage of participants who have microscopically negative margins (no tumor at/near the edge of what is resected) at the time of surgical resection

measured from the first day of treatment to the day when conclusive evidence of new disease is found

For patients who undergo complete resection, those who have no evidence of residual viable tumor in the surgical specimen will be declared to have achieved a complete pathologic response (pCR), and the overall percentage of patients with pCR will be determined.

Overall survival (OS) is the duration from start of treatment to time of death from any cause.

Massachusetts General Hospital

Clinical Director, MGH Cancer Center

Adverse events seen in this study were not significantly different from those reported by Waddell T, et. al in Lancet Oncol. 2013 May;14(6):481-9. (NCT00824785). Therefore, only grade 3 and 4 adverse events have been reported here.

Panitumumab in Combination with Epirubicin, Oxaliplatin and Capecitabine (EOX-P)

Epirubicin, Oxaliplatin, Capecitabine, Panitumumab Treatment

Age, Categorical

Age, Continuous

Sex: Female, Male

United States

Region of Enrollment

17 patients with adenocarcinoma of the stomach were enrolled on this study of perioperative EOX-P.

This study was stopped early due to poor tolerability. We will not further study this regimen in this patient population.

David P. Ryan

Safety and Tolerability

Panitumumab in Combination with Epirubicin, Oxaliplatin, and Capecitabine (EOX-P) Chemotherapy.

Spots Global Cancer Trial Database for Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma

Trial Identification

Conditions

Interventions

Study Description

Keywords

Eligibility

Locations

Contact Details

Useful links and downloads for this trial